Barry Lab
Principal Investigator: Kevin C Barry
Institution: Fred Hutch Cancer Center (Seattle, WA)
Primary Subfield: Molecular & Cell Bio
Recruitment Status: ✅ Hiring Postdocs
Research Focus
PROJECT SUMMARY Current immunotherapies, such as anti-PD-1 immunotherapy, have low objective responses in patients, necessitating the development of novel therapies that boost immune responses to cancer and responses to these treatments. Further, most immunotherapies in the clinic, anti-PD-1 immunotherapy included, predominantly act on T cells. While combinations of T cell-directed therapies can lead to excellent outcomes for some, most patients still have no objective responses to combinations of these immunotherapies. Thus, it is imperative to identify novel therapeutic targets that work synergistically with anti-PD-1 immunotherapy and other T cell-directed therapies. Natural killer (NK) cells are innate lymphocytes that can control tumors through direct cytotoxicity or their immunomodulatory production of cytokines and chemokines. NK cell abundance in the tumor correlates with increased patient survival and patient responses to immunotherapies. We previously found that a key immunomodulatory function of NK cells is their production of the cytokine FLT3LG which regulates type 1 conventional dendritic cell (cDC1) abundance in the tumor microenvironment (TME). cDC1s are an importan…
Active NIH Awards
- 4R01CA283080-03: Dissecting the immunomodulatory effects of NK cells on immune responses to cancer (2026)
- 5R01CA283080-02: Dissecting the immunomodulatory effects of NK cells on immune responses to cancer (2025)
- 1R01CA283080-01A1: Dissecting the immunomodulatory effects of NK cells on immune responses to cancer (2024)
Explore 700+ US Biology Labs on FindBioLabs.com